APEG-PCL Nanoparticles Containing Rifampicin Target Dopaminergic Neurons to reduce α-synuclein aggregation
Objective: There were accumulating evidence proving that rifampicin could protect neurons from apoptosis in Parkinson's disease in-vitro model by regulating SUMO modification of α-synuclein. However,…Delayed Osmotic Demyelination Syndrome- An Evolving Spectrum
Objective: To report a case of osmotic demyelination syndrome (ODS) with continuing clinical and radiological worsening beyond its previously established temporal course. Background: ODS is…Medication safety in Parkinson’s disease patients: evaluation of recommendations for decision support in the national drug-disease interaction database
Objective: Objective: Drug-disease interactions in Parkinson's disease patients can give rise to situations where a drug may have negative effects on both motor- and non-motor…Development of C-terminal α-Synuclein Vaccine for Treatment and Prevention of Parkinson’s Disease and Other Synucleinopathies
Objective: Prothena is developing active vaccine candidates targeting α-synuclein (α-syn) epitopes shown in clinical and/or preclinical studies to disrupt synuclein pathology. These vaccines, which target…Distribution of rapid eye movement (REM) sleep without atonia (RWA) across the REM cycles.
Objective: This study aimed to evaluate whether rapid eye movement )REM( sleep without atonia )RWA( is similar throughout multiple REM cycles during one night. Background:…Exenatide protects iPSC-derived dopaminergic neurons with A53T mutation through restoration of insulin signaling
Objective: Here we sought to investigate mechanisms by which insulin resistance affects PD pathogenesis in-vitro, and whether restoration of insulin signaling, using GLP-1 agonist exenatide…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.